2025-09-11 - Analysis Report
Okay, here's an analysis of TEM based on the provided data, presented in English with a focus on key metrics and a concise summary:

**TEM (Unknown Company) Analysis**

**Company Overview:** Unknown Company, likely operating in the healthcare or technology sector based on news and study mentions.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (TEM):** 46.73%
*   **Cumulative Return (VOO):** 18.92%
*   **Spread:** 23.9 (Max: 103.1, Min: -25.2, Relative Spread: 38.3)

**Analysis:** TEM has significantly outperformed the S&P 500 over the observed period. The relative spread of 38.3 indicates the current outperformance is in the lower end of its historical range, suggesting the potential for further gains relative to the S&P 500, although it's below the median.

**Key Metrics:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap (B) |
|------------|-------|-------|-------|------|---------|
| 2023-2025 | 47.0% | 75.0% | 29.0% | 0.0  | 13.6    |

**Analysis:**

*   **CAGR (47.0%):**  High annual growth rate, indicating strong potential.
*   **MDD (75.0%):** Very high Maximum Drawdown, suggesting significant volatility and risk.
*   **Alpha (29.0%):** Substantial Alpha indicates the stock's returns are independent of market movements and are driven by company-specific factors.
*   **Beta (0.0):** Beta of 0 suggests that the stock is not correlated with the market's volatility.
*   **Cap (B):** $13.6 billion market capitalization suggests it's a mid-cap company.

**2. Recent Price Action**

*   **Current Price:** 81.01
*   **Last Market Data:** Price: 78.16, Previous Close: 81.01, Change: -3.52
*   **5-Day Moving Average:** 79.05
*   **20-Day Moving Average:** 75.57
*   **60-Day Moving Average:** 66.32

**Analysis:** The price closed lower at 78.16, a significant drop from the previous close of 81.01. The current price is above all moving averages, suggesting an uptrend, but the recent drop indicates a potential pullback.

**3. Technical Indicators**

*   **MRI:** 0.3261 (Low Risk)
*   **RSI:** 64.95 (Approaching Overbought)
*   **PPO:** 0.0919 (Positive Momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-Day Relative Spread Change:** +7.4 (Short-Term Increase)
*   **Expected Return:** NaN

**Analysis:**

*   The MRI indicates a low-risk market environment.
*   The RSI is approaching overbought territory, suggesting a possible correction.
*   The PPO indicates positive momentum.
*   The Hybrid Signal suggests a buy recommendation, but with caution due to the MRI.
*   The increase in the 20-day relative spread suggests short-term positive momentum.
*   The `price': 78.16, 'previousClose': 81.01, 'change': -3.52` indicate a recent sharp price decline, which needs to be carefully monitored.
*   Expected Return is `NaN`, indicating that the system cannot estimate the long-term return at this moment.

**4. Recent News & Events**

*   **Positive:** Strong Q2 revenue growth, partnerships with Northwestern Medicine for AI-powered care, validation of AI algorithm for cancer therapy selection.
*   **Neutral:** Participation in Morgan Stanley Healthcare Conference.
*   **Negative:** None in the provided news.

**Analysis:** Recent news is predominantly positive, focusing on revenue growth, AI technology advancements, and partnerships.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (2.15 rating)
*   **Target Price:** Average: $72.73, High: $90.00, Low: $60.00

**Analysis:** Analyst consensus is "Buy," but the average target price is *below* the current price, suggesting limited upside potential or even a possible overvaluation in the analysts' view. No recent rating changes were provided.

**5. Earnings Analysis**

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-08-08 | -0.22 | -0.23    |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:**  TEM is currently unprofitable. Recent EPS results have generally been slightly better than expected, which is a positive sign.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE        |
|------------|---------|------------|
| 2025-06-30 | $0.31B  | -13.84%    |
| 2025-03-31 | $0.33B  | -20.86%    |
| 2024-12-31 | $0.06B  | -23.10%    |
| 2024-09-30 | $0.05B  | -141.16%   |
| 2024-06-30 | $0.10B  | -562.04%   |

**Analysis:**

*   **Revenue:**  Strong revenue growth trend is evident.
*   **Profit Margin:**  Impressively high and relatively stable profit margins.
*   **Equity:** Equity fluctuates, but is trending upwards
*   **ROE:**  Negative ROE confirms the company is currently unprofitable, though improving compared to a year ago.

**7. Overall Summary**

TEM has significantly outperformed the S&P 500, driven by strong revenue growth and high profit margins. Recent news is mostly positive, highlighting AI advancements and strategic partnerships. However, the company is currently unprofitable with very high volatility (MDD 75%). Analyst consensus is "Buy," but the average target price is *below* the current price. The recent sharp price decline needs to be monitored. The Hybrid signal suggests a cautious buy.
